Walid Lakhdar, country business unit head for Tunisia and Libya at Pfizer, stresses the company’s ongoing dedication to patients in Tunisia. This was illustrated by the significant investments Pfizer has made in Tunisia after the revolution and still continues to make. Lakhdar talks about Pfizer’s successful partnerships in the country with key stakeholders, which positively impact the lives of patients. In addition, he sheds light on Pfizer’s commitment to ensuring that patients in Libya have access to life saving medicines regardless of the turmoil in the country.
Mr. Lakhdar, how does Pfizer view its responsibility to the Tunisian people and the country?
"Tunisia might be a small country geographically on the global scale; however, we never stopped considering it as a significant market with patients that rely on our quality medications."
